| 马温惠杨卫东李桂玉汪静△.生长抑素受体介导的放射性核素治疗[J].,2012,12(25):4956-4960 |
| 生长抑素受体介导的放射性核素治疗 |
| Peptide Receptor Radionuclide Therapy with Somatostatin ReceptorAnalogues |
| |
| DOI： |
| 中文关键词: 神经内分泌肿瘤 生长抑素受体 内放射治疗 放射性核素治疗 |
| 英文关键词: Neuroendocrine tumour Somatostatin receptor Internal radiotherapy Radionuclide therapy |
| 基金项目:国家自然科学基金资助项目（30970846）；国家重点基础研究发展计划(2011CB707704) |
|
| 摘要点击次数: 807 |
| 全文下载次数: 1825 |
| 中文摘要: |
| 生长抑素受体介导的放射性核素治疗（peptide receptor radionuclide therapy, PRRT)是用于不能手术治疗或有远处转移的胃、
肠和胰腺等神经内分泌肿瘤病人的一种新型治疗方法，本文旨在综述近年来不同核素标记生长抑素类似物的临床评价及相关研
究。 |
| 英文摘要: |
| The somatostatin receptor is strongly over-expressed in most neuroendocrine tumours （NETs）, resulting in high tumour-
to-background ratios. Peptide receptor radionuclide therapy （PRRT）with radiolabelled somatostatin analogues is an emerging and
convincing treatment modality for patients with unresectable, somatostatin-receptor-positive NETs. Using radiolabelled somatostatin analogues
for imaging became the gold standard for staging of NETs. This article reviews the effectiveness and safety of the different radiolabelled
somatostatin analogues used. Furthermore, clinical issues - including indication, timing and side-effect of therapy - are discussed.
Finally, important directions for future research are mentioned to illustrate new strategies for increasing therapy ef覱cacy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
